Atezolizumab (Tecentriq)
PD-L1 checkpoint inhibitor for lung cancer, liver cancer, bladder cancer, and other solid tumours.
What is Atezolizumab?
What it targets
PD-L1 on tumour cells and immune cells. By blocking this interaction, atezolizumab restores T-cell-mediated immune attack against cancer.
Who it may help
Patients with PD-L1-expressing tumours in approved settings. NSCLC (post-surgery, first-line), SCLC (first-line), HCC (unresectable/metastatic), and other eligible cancers.
Why testing matters
PD-L1 expression guides treatment selection and dosing. Patients with EGFR or ALK mutations need molecular testing to rule out benefit from targeted therapy first.
Which cancers can atezolizumab treat?
Atezolizumab is approved for multiple cancer types in different treatment settings.
| Non-small cell lung cancer (NSCLC) | Adjuvant (post-surgery) for stage II-IIIA with PD-L1 expression. First-line monotherapy for metastatic disease with PD-L1 ≥50%. First-line combination with chemotherapy and bevacizumab regardless of PD-L1 level. Second-line for disease progression after chemotherapy. |
| Small cell lung cancer (SCLC) | First-line in combination with carboplatin and etoposide for extensive-stage SCLC. Maintenance with lurbinectedin plus atezolizumab after induction therapy. NCCN 2026 lists this as a preferred primary option. |
| Hepatocellular carcinoma (HCC) | First-line in combination with bevacizumab for unresectable or metastatic HCC without prior systemic therapy. Adjuvant use after resection or ablation in selected cases. |
| Urothelial carcinoma (bladder cancer) | Locally advanced or metastatic disease in patients who have progressed after platinum chemotherapy. Also approved for muscle-invasive bladder cancer after cystectomy with ctDNA-confirmed MRD. |
| Melanoma | BRAF V600 mutation-positive unresectable or metastatic melanoma, typically in combination with cobimetinib and vemurafenib. |
| Alveolar soft part sarcoma (ASPS) | FDA-approved as monotherapy for unresectable or metastatic ASPS, regardless of prior treatment history. |
Are you eligible for atezolizumab?
Eligibility depends on confirmed cancer type, treatment line, PD-L1 status, molecular mutations, and organ function.
- Confirmed diagnosis of an eligible cancer type (NSCLC, SCLC, HCC, urothelial, melanoma, ASPS, or other approved indications).
- PD-L1 testing completed. For many indications, PD-L1 expression level guides whether atezolizumab is used alone or in combination.
- Molecular testing for EGFR and ALK mutations (lung cancer). If driver mutations are present, target therapy is usually tried first.
- Adequate liver function. For HCC patients, Child-Pugh grade A-B is typical; grade C patients need specialist assessment.
- Adequate kidney function. Creatinine and GFR should be monitored; dose adjustment is not typically needed but close monitoring is essential.
- No uncontrolled autoimmune disease, active infection, or pregnancy. Previous organ transplant history requires careful consideration.
How does atezolizumab work?
- Blocking the PD-L1 checkpoint
- Reactivating T-cell immunity
- Sustained anti-tumour attack
- Improving outcomes with combinations
Atezolizumab works by unleashing your immune system, not by directly killing cancer cells.
Tests required before starting atezolizumab
These tests establish baseline status, confirm eligibility, and guide treatment planning.
| Tumour biopsy and pathology | Confirms cancer diagnosis, histology, and type. Essential for PD-L1 and molecular testing. |
| PD-L1 immunohistochemistry (IHC) | Measures PD-L1 expression using an FDA-approved assay (e.g. Ventana SP263). Result guides whether atezolizumab is used alone or in combination. |
| Molecular testing (lung cancer) | EGFR, ALK, ROS1, BRAF, KRAS mutations and next-generation sequencing (NGS). Required for NSCLC to identify driver mutations and guide therapy sequence. |
| Complete blood count (CBC) | Baseline white blood cells, haemoglobin, platelets. Used to monitor for atezolizumab-related bone marrow effects during treatment. |
| Liver function tests (LFT) | Baseline AST, ALT, bilirubin, albumin. Essential for all patients; particularly important before HCC treatment with atezolizumab and bevacizumab. |
| Kidney function tests | Creatinine, eGFR, electrolytes. Baseline renal function guides safe dosing and monitoring. Proteinuria monitoring is important if bevacizumab is also used. |
| Thyroid function and glucose | TSH, free T4, fasting glucose. Atezolizumab can cause hypothyroidism and hyperglycaemia; baseline values help detect changes early. |
| Baseline imaging | CT chest/abdomen, PET-CT, MRI, or other imaging per cancer type. Documents baseline disease burden for response assessment during treatment. |
How is atezolizumab given?
Atezolizumab is administered as an intravenous (IV) infusion or subcutaneous injection, depending on indication and preference.
| Intravenous (IV) infusion | Standard formulation (Tecentriq). Typical dose is 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. Infusion time is approximately 30-60 minutes. Given in a hospital or day-care infusion centre. |
| Subcutaneous injection | Newer formulation (Tecentriq Hybreza, combining atezolizumab with hyaluronidase). Dose is 1875 mg with 30,000 units hyaluronidase injected subcutaneously in the thigh every 3 weeks over approximately 7 minutes. Can sometimes be self-administered at home or clinic. |
| Treatment duration in adjuvant NSCLC | Typically 16 cycles of atezolizumab (approximately 12 months on a 3-weekly schedule) following platinum chemotherapy. Duration varies depending on response and tolerability. |
| Treatment duration in metastatic disease | Treatment continues until disease progression or unacceptable toxicity. Some patients may continue for years if stable or responding; others may need treatment breaks for toxicity management. |
| Combination regimens | When combined with chemotherapy (carboplatin, etoposide, paclitaxel) or bevacizumab, atezolizumab is typically given on day 1 before chemotherapy or with bevacizumab on the same day. Specific schedules depend on the indication. |
| Missed infusions or injections | If a dose is missed, arrange it as soon as possible. Avoid doubling up. Prolonged delays between doses may reduce efficacy; contact your oncology team if delays exceed 2 weeks. |
Clinical evidence and benefits
Atezolizumab has demonstrated survival benefits and response improvements across multiple cancer types.
| Disease-free survival (adjuvant NSCLC) | In the IMpower010 trial, adjuvant atezolizumab improved disease-free survival in stage II-IIIA NSCLC patients, particularly in those with higher PD-L1 expression (≥50% of tumour cells). |
| Overall survival (metastatic NSCLC) | Atezolizumab monotherapy provides overall survival benefit in metastatic NSCLC regardless of PD-L1 level. Combined with chemotherapy and bevacizumab (IMpower150 trial), median OS is substantially longer than chemotherapy alone. |
| First-line SCLC outcomes | Atezolizumab plus carboplatin and etoposide is now the standard first-line regimen for extensive-stage SCLC per NCCN 2026. Maintenance with lurbinectedin and atezolizumab further improves progression-free survival. |
| HCC response and survival | Atezolizumab plus bevacizumab improves response rates and overall survival in unresectable or metastatic HCC compared to sorafenib, becoming the preferred first-line option for most patients without prior systemic therapy. |
| Quality of life and symptom control | Compared to chemotherapy, atezolizumab-based regimens often allow better symptom control and maintenance of performance status, with fewer chemotherapy-related toxicities like severe nausea or hair loss. |
Individual responses vary substantially. These represent published clinical trial data; your personal outcome depends on cancer characteristics, immune fitness, and tolerability.
Side effects of atezolizumab
Most side effects are manageable with supportive care. Atezolizumab can cause immune-mediated inflammation; report new or worsening symptoms immediately.
| Fatigue or weakness | Common (up to 50% of patients). Usually mild to moderate. Manage with rest, nutrition, and gentle activity. |
| Cough or shortness of breath | Can occur in 10-20% of patients. May indicate pneumonitis (lung inflammation), which requires urgent evaluation and possible corticosteroid treatment. |
| Rash or itching | Occurs in 10-20% of patients. Usually mild and managed with topical steroids or antihistamines. Severe rashes may require treatment interruption. |
| Diarrhoea or constipation | Occurs in 10-30% of patients. Severe diarrhoea (>10 stools/day) may indicate colitis and requires urgent medical attention. |
| Nausea and decreased appetite | Common. Less severe than with chemotherapy. Manage with anti-nausea medicines, small frequent meals, and ginger or peppermint when appropriate. |
| Thyroid changes | Hypothyroidism occurs in 10-15% of patients. TSH and free T4 are monitored regularly. Most patients can be managed with levothyroxine supplementation. |
| Infusion-related reactions | Rare but possible. Symptoms include fever, chills, flushing, chest discomfort, or wheezing during or shortly after infusion. Managed with slower infusion rates, premedication, or IV fluids. |
| Liver or kidney dysfunction | Immune-mediated hepatitis or nephritis can occur but are uncommon. Regular blood tests monitor liver and kidney function. |
Contact your doctor immediately if you develop:
- Persistent cough, chest pain, or severe shortness of breath (possible pneumonitis).
- Severe diarrhoea (>10 stools/day), blood in stool, or severe abdominal pain (possible colitis).
- Jaundice, dark urine, severe nausea, or right-sided abdominal pain (possible hepatitis).
- Severe headache, vision changes, confusion, or fainting (possible brain or pituitary inflammation).
- High fever, chills, signs of infection, or extreme fatigue (possible bone marrow or immune complications).
Safety precautions and drug interactions
Tell your oncologist about all medicines, supplements, and medical history before starting atezolizumab.
- Active or previous autoimmune disease (lupus, rheumatoid arthritis, inflammatory bowel disease, etc.). Atezolizumab may reactivate these conditions.
- Organ transplant history or immunosuppressive therapy. These increase risk of immune-related complications.
- Hepatitis B or C, HIV, or active infection. Specialist advice is needed; some infections may worsen with atezolizumab.
- Lung disease or interstitial lung disease. Atezolizumab can cause pneumonitis; baseline lung function tests may be needed.
- Diabetes or thyroid disease. Atezolizumab can cause hyperglycaemia and hypothyroidism; closer monitoring is needed.
- Pregnancy or breastfeeding. Atezolizumab causes foetal harm; effective contraception is essential. Do not breastfeed while on atezolizumab.
- Concurrent steroid or immunosuppressive use. These may reduce atezolizumab efficacy or complicate immune-related side effect management.
Atezolizumab combination treatments
Atezolizumab is often combined with other agents to improve outcomes, depending on cancer type and treatment setting.
| NSCLC: carboplatin, paclitaxel, and bevacizumab (ABCP) | Approved for first-line metastatic non-squamous NSCLC regardless of PD-L1 level. IMpower150 trial showed superior overall survival compared to chemotherapy and bevacizumab alone. |
| SCLC: carboplatin and etoposide (first-line induction) | Standard first-line regimen for extensive-stage SCLC. Atezolizumab is given with chemotherapy, then continued as maintenance or switched to lurbinectedin plus atezolizumab. |
| SCLC: lurbinectedin (maintenance) | Atezolizumab plus lurbinectedin as maintenance therapy after induction chemotherapy and atezolizumab. Extends progression-free survival compared to observation alone. |
| HCC: bevacizumab (first-line) | Atezolizumab plus bevacizumab is the standard first-line regimen for unresectable or metastatic HCC. Superior to sorafenib in overall survival. |
| Melanoma: cobimetinib and vemurafenib (BRAF V600 mutant) | Atezolizumab is combined with targeted therapy (cobimetinib and vemurafenib) for BRAF-mutated melanoma, enhancing response and survival. |
| Sequential and switching regimens | If atezolizumab-based therapy reaches progression, patients may switch to chemotherapy, other immunotherapy combinations, or targeted therapy depending on biomarkers and prior treatment. |
If atezolizumab stops working
Cancer can develop resistance to atezolizumab. Understanding the mechanisms guides next-line treatment.
| Primary resistance (no response from the start) | Some cancers do not respond to PD-L1 blockade despite adequate dosing. This may be due to low tumour mutation burden, high VEGF expression, or other immune-suppressive features. |
| Acquired resistance (response followed by progression) | Tumours may develop mechanisms to evade immune attack, including loss of tumour antigens, increased immunosuppressive cells, or upregulation of other checkpoint pathways (e.g. TIM-3, LAG-3). |
| Diagnostic approaches to resistance | Repeat imaging confirms true progression. Repeat biopsy or liquid biopsy (circulating tumour DNA) may identify new mutations or biomarkers guiding next therapy. PD-L1 status may change. |
| Next-line options for NSCLC | If atezolizumab fails in NSCLC, options include another immunotherapy (pembrolizumab, nivolumab if not previously used), chemotherapy, targeted therapy if new drivers are found, or clinical trials. |
| Next-line options for SCLC | If first-line atezolizumab-based therapy progresses, chemotherapy (topotecan, irinotecan) or novel agents (lurbinectedin if not used, T-DXd for HER2+ disease, erdafitinib for FGFR3 alterations) may be considered. |
| Next-line options for HCC | If atezolizumab-bevacizumab fails, options include sorafenib, lenvatinib, regorafenib, or other targeted agents. TACE, TARE, or liver transplant may be considered depending on disease extent. |
Cost of atezolizumab by country
Atezolizumab cost varies dramatically by country, insurance, and whether you receive branded Tecentriq or biosimilars.
| USA | Branded Tecentriq (Genentech) costs approximately USD 12,000-15,000 per infusion. IV or subcutaneous formulation. Most insurance covers with prior approval. Patient assistance programmes available for uninsured or underinsured patients. |
| Europe and UK | NHS and national insurance schemes cover atezolizumab for approved indications. Cost to patient is typically minimal (copay only) or zero depending on country and indication. Private pay is approximately EUR 8,000-12,000 per infusion. |
| India | Imported Tecentriq and some biosimilars available through major cancer centres. Cost ranges from INR 150,000-250,000 per infusion depending on supply and hospital. Generic versions are not widely available yet; some patient assistance programs exist. |
| China | Atezolizumab is available through major hospitals and medical centres. Cost approximately CNY 30,000-50,000 per infusion after negotiated pricing and provincial reimbursement. Exact price varies by city and insurance status. |
| Southeast Asia (Thailand, Vietnam, Philippines) | Available through private and public hospitals. Cost approximately USD 3,000-8,000 per infusion depending on country and supply. Some insurance coverage available; many patients are self-pay. |
Availability of atezolizumab globally
Atezolizumab is approved in most major oncology markets, but exact indications, formulations, and reimbursement vary.
USA
FDA-approved for NSCLC (adjuvant, first-line monotherapy, first-line combinations), SCLC, HCC, urothelial cancer, melanoma, and ASPS. IV and subcutaneous formulations available. Strong insurance coverage; patient assistance programmes for uninsured.
Europe
EMA-approved for NSCLC, SCLC, urothelial cancer, TNBC (note: TNBC approval may vary), HCC, melanoma, and other indications. Available as IV or subcutaneous injection. National health systems cover approved indications.
China
NMPA-approved for multiple indications including SCLC and others. Available through major hospitals and cancer centres. Pricing negotiated; coverage through national health insurance varies by province. Broader indications being reviewed.
India
Atezolizumab is available through major oncology centres and importers. Not yet widely generic. Approved indications and reimbursement should be verified locally. CancerFax can help identify access pathways.
Southeast Asia
Available in Thailand, Vietnam, Philippines, and other countries through private and public hospital networks. Approval status and indications vary; cost and insurance coverage differ by country.
Atezolizumab in current clinical trials
Atezolizumab is being studied in combination with new agents and in emerging cancer types.
| Novel immunotherapy combinations | Trials are exploring atezolizumab combined with other checkpoint inhibitors (e.g. anti-CTLA-4, anti-LAG-3, anti-TIM-3) to overcome resistance and improve response rates. |
| Early-stage NSCLC perioperative therapy | Studies are investigating neoadjuvant atezolizumab-based regimens before surgery in early-stage NSCLC to improve disease-free and overall survival. |
| HCC adjuvant and conversion therapy | Trials examining atezolizumab-bevacizumab as adjuvant therapy after resection, and as conversion therapy to make unresectable HCC resectable. |
| Biomarker-driven strategies | Studies refining which patients benefit most from atezolizumab based on PD-L1 levels, tumour mutation burden, immune cell infiltration, and other emerging biomarkers. |
Your treatment journey with atezolizumab
Diagnosis and molecular testing
First oncology consultation
Pre-treatment assessment
Starting atezolizumab
Early monitoring (weeks 1-12)
Ongoing treatment and monitoring
Managing side effects
Treatment completion or progression
Questions to ask your oncologist about atezolizumab
- What is my PD-L1 status and what does it mean for using atezolizumab?
- Will I receive atezolizumab alone or in combination with other drugs?
- How long will I be on atezolizumab treatment?
- What side effects should I report immediately and which can wait?
- How often will I have imaging and blood tests?
- What happens if atezolizumab does not work or if I develop resistance?
- Are there patient assistance programmes if atezolizumab becomes unaffordable?
- Can I ever stop atezolizumab treatment?
How CancerFax supports atezolizumab patients
CancerFax helps patients and families navigate atezolizumab access, side effect management, and international treatment options.
| Report review and interpretation | Upload your PD-L1 test result, biopsy, molecular testing, and baseline scans. Our team reviews and explains what they mean for your atezolizumab eligibility and treatment planning. |
| Specialist connection | We connect patients with oncologists experienced in atezolizumab-based regimens for NSCLC, SCLC, HCC, and other cancers across India, China, Southeast Asia, and internationally. |
| Second opinion | If unsure about atezolizumab recommendations, whether to continue if side effects are severe, or whether you are a candidate, CancerFax arranges expert second opinions. |
| Access and cost navigation | We help identify atezolizumab availability in your country, verify insurance coverage, explore patient assistance programmes, and guide international treatment options if needed. |
| Side effect management support | We provide guidance on managing common side effects, help you distinguish between manageable toxicity and urgent warning signs, and coordinate with your oncology team on symptom management. |
| International treatment coordination | For patients seeking treatment outside their home country, CancerFax manages hospital selection, medical record transfer, visa support, translation, and follow-up care coordination. |
Frequently asked questions about atezolizumab
Common questions from patients and caregivers
Atezolizumab is an immunotherapy that blocks PD-L1, a protein that helps cancer cells hide from the immune system. Unlike chemotherapy, which broadly kills fast-dividing cells, atezolizumab helps your own immune cells recognise and attack cancer more effectively. This targeted approach often means fewer side effects like hair loss or severe nausea.
Response timing varies by cancer type. In NSCLC, response is typically evaluated by imaging at 8-12 weeks. In SCLC, response is assessed after 2-3 cycles of chemotherapy. Your oncologist will explain your personal treatment milestones and monitoring schedule based on your cancer type and treatment plan.
Yes, PD-L1 testing is often required to determine if atezolizumab is right for you. Your tumour tissue is tested using an approved assay to measure PD-L1 expression level, which guides dosing and combination decisions. Ask your oncologist which test was done on your biopsy and what your result means for your treatment options.
Yes. Atezolizumab is frequently combined with chemotherapy (carboplatin, paclitaxel, etoposide), bevacizumab, or other agents depending on your cancer type and treatment line. Some combinations are given together; others are sequential. Your oncologist will explain which approach is planned for you and why.
If your cancer progresses while on atezolizumab, your oncologist will review imaging to confirm true progression and repeat biopsies or liquid biopsies to understand why. Next-line options may include switching to a different immunotherapy, chemotherapy, targeted therapy if a driver mutation is found, or clinical trials. Each option is discussed with your team.
No. Atezolizumab can harm a developing foetus and must not be used during pregnancy. Effective contraception is required throughout treatment and for at least 5 months after your last dose. Do not breastfeed while on atezolizumab or for 5 months after. Discuss these restrictions and family planning with your oncologist before starting.
Atezolizumab is available in many countries including China, India, and across Asia. Availability, pricing, and approval status vary by location and indication. CancerFax can help you understand access pathways in your country, connect with hospitals that use atezolizumab, and explore cost options or patient assistance programs.